Valuation models
price $41.98 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused32.90 – 55.7941.671% overvaluedDCF · Perpetuity growth · 10y39.08 – 65.0249.0314% undervaluedDCF · EBITDA exit · 5y61.95 – 68.1164.9535% undervaluedDCF · EBITDA exit · 10y64.60 – 76.8970.4540% undervaluedP/E · peers74.83 – 97.5186.1751% undervaluedP/E · own history151.47 – 216.19184.9977% undervaluedPEG—51.7219% undervaluedEV/EBITDA · peers69.56 – 109.8589.7053% undervaluedEV/Revenue · peers55.06 – 69.2964.6535% undervaluedEarnings power value9.13 – 17.4812.45237% overvaluedWall St. consensus target—49.5015% belowCost of capital (WACC)—7.28%—
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
41.67
Boston Scientific closed at $41.98 — overvalued by 1% vs model.
32.90the model's range55.79
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
12.45 – 184.99
Wall St. target
49.50 15% below
Above model, 1y
3 of 30 days
How it is valued
Valued asMature & Stable
Moderate growth (~19% recent)Moderate margins (14% net margin)Highly cyclical earningsStrong FCF yield (6.0%)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.